NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
about
NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in SpainSimeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).Era of direct acting anti-viral agents for the treatment of hepatitis C
P2860
NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
NS3 protease polymorphisms and ...... wide treatment-naïve subjects.
@en
type
label
NS3 protease polymorphisms and ...... wide treatment-naïve subjects.
@en
prefLabel
NS3 protease polymorphisms and ...... wide treatment-naïve subjects.
@en
P2093
P2860
P356
P1476
NS3 protease polymorphisms and ...... wide treatment-naïve subjects.
@en
P2093
P2860
P304
P356
10.1111/JVH.12503
P577
2016-01-18T00:00:00Z